How GLP-1 Medications Change the Clinical Baseline Before focusing on specific imaging findings, it is important to recognize that GLP-1 therapies alter what clinicians consider baseline. Weight, appetite, glycemic control, and gastrointestinal motility shift over weeks to months, not years
Code availability Data processing and statistical analyses were performed using the open-source software R (version 4.5.1)
Its anabolic and growth-promoting effects are largely indirect, primarily via stimulation of hepatic IGF-1 production, whilst its direct metabolic effects, particularly those related to lipid metabolism and adipose tissue regulation, are believed to be mediated by specific domains within the GH molecule itself
DKA occurs when severe insulin deficiency leads to uncontrolled lipolysis, excessive ketone production, hyperglycaemia, and metabolic acidosis
These findings add further support to a growing body of evidence that suggests that Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) may modulate the human reward system by interacting with receptors in brain regions associated with dopamine signaling
In some cases the pink may fade
